SPRO
Spero Therapeutics, Inc.
Key Financials
Net Income
$8.6M
↑ 112.5%
Operating Income
$6.3M
↑ 108.6%
Revenue
$66.8M
↑ 39.2%
EPS (Diluted)
$0.15
↑ 111.8%
Total Liabilities
$9.9M
↓ 84.6%
Cash & Equivalents
$40.3M
↓ 23.9%
Total Assets
$68.9M
↓ 37.7%
Shareholders' Equity
$59.0M
↑ 28.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| 4 | 5/6/2026 | View on SEC |
| ARS | 4/27/2026 | View on SEC |
| DEFA14A | 4/27/2026 | View on SEC |
| DEF 14A | 4/27/2026 | View on SEC |
| PRE 14A | 4/13/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 10-K | 3/26/2026 | View on SEC |
| 4 | 2/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SPRO |
| Company Name | Spero Therapeutics, Inc. |
| CIK | 1701108 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-242-1600 |